






Product Design & Development Plan – Interactive Guide

How to Use This Document

- The diagram on the following pages shows the key stages (along the top), and key processes (down the lefthand side) involved with a typical medical device design project
- The arrows represent the interactions between the various processes
- Click on the **white heading boxes** to find out more about each process
- Press  at the bottom of the page to return to the full process diagram
- Diagram Key
 - Colour-fill boxes: services offered by eg technology
 - White-fill boxes: services to be provided externally – eg can recommend third parties if requested



Please note this document is intended to be used as a framework only, and each project should be individually tailored and adapted.



KEY


3rd Party Process

eg technology Process



© eg technology 2023





KEY


3rd Party Process

eg technology Process



© eg technology 2023





There are additional aspects that happen in parallel (and directly interact) with the core design and development activities. The first of these is human factors/usability engineering. This stream is based on IEC 62366, the usability engineering process. This happens right from the beginning all the way through your programme.


Start with primary user research, making sure you speak to real users and understand their needs. Challenge your assumptions – you may well be surprised. Next are the use-risk analysis and user interface specification tasks. The idea of usability engineering is really to prove that your user interface is safe (and usually also intuitive) to use. You start by understanding the risks associated with use error, and from that define the user interface specification to design to.

During the detailed design and development stages, you will test the prototypes that you make on real users; these are *formative* evaluations. The results of the formative evaluations should feedback into your next detailed design iteration. Remember to update your use risk analysis as you go, because you will have learnt new things.

The pilot units produced in the transfer to manufacture stage need to be “production representative”, including with representative training, labelling, IFU (instructions for use) and packaging. This must be ready for your *summative* evaluation, which is the final evaluation, aiming to prove that your device is safe to use. You then compile the documents from the whole process with a summary report in your usability engineering file.

You will notice that you should be interacting with real users all the way through – that is really the key here. It will ensure that you are making the right product, right from the beginning, and that it will be safe and intuitive for your users.





Risk management is another very important stream in medical & IVD product development, particularly in terms of the regulations. The process described here is in line with ISO 14971, with which you will need to comply. Once again, you can see different elements happening throughout the programme.


Starting with a risk management plan, outline what you're going to do, when, what your scoring metrics are, what your definitions are, and so on.

In the early concept generation stages, even though you don't have a detailed design, you can start to identify the top-level hazards and harms that your product presents. This is then followed by a preliminary hazard analysis to identify risks and hazardous scenarios. The mitigations to those risks should feed back into the design.

In a later detailed design stage, we typically do a dFMEA (design Failure Mode Effects Analysis), which goes into more detail. As you progress into the transfer-to-manufacturer phase, there might be other types of FMEA you want to do as well, such as a process FMEA, or a transport FMEA, depending on your product.

The aim of this process is to mitigate the risks as best as possible, but you can't remove them altogether. So the last few stages include a residual risk assessment and a risk-benefit analysis. It is important that this is done by people with the relevant knowledge and expertise, and typically also relevant clinical expertise to really assess whether the benefits suitably outweigh the residual risks for your product. This gets compiled into a risk management report at the end.





The verification & validation stream shown here describes what is commonly known as the "V model". If you are not yet familiar with the V model or the basics of requirements management, check out our blog on the subject [here](#).


The V model is about identifying your user needs and documenting them in a User Requirement Specification (URS). Using that, and other information you have, you can define your design inputs or Product Requirement Specification (PRS), which is about the functional and performance requirements of your product.

The most important thing to remember is that you *verify* against your PRS and *validate* against your URS.

Don't forget compliance testing, which is the part of your verification testing which focuses on the standards that relate to your product. For example, this might include EMC (electromagnetic compatibility) testing, biocompatibility testing or IEC 60601 testing to name just a few. This will depend on which standards apply to your product, so it is important to identify those standards early on, and list them in your requirement specifications.

Be sure to include them in your verification and validation test plan and timeline along with your other formal verification (e.g. benchtop functional tests) and validation testing (clinical evaluation & summative usability study).






Quality is multi-faceted and closely related to many of the other streams. Firstly, there is the overarching task of establishing your quality management system (QMS) in line with ISO 13485 or the FDA equivalent (this task is highlighted in grey). Secondly, it is crucial to have a strategy in place for ISO 13485 certification which, as the legal manufacturer, is a requirement before your product can go to market. Many companies prefer to appoint an ISO 13485-accredited partner to act as the legal manufacturer on their behalf.

Your QMS will include all the different processes/activities which need to be directed or controlled (directly or indirectly) to achieve the intended results, including: requirements management, verification and validation, risk management, supplier selection & evaluation, manufacturing and quality control, change control, post-market surveillance and so on. As well as integrating each of these processes into your QMS, you will also need to demonstrate that you have actually *used* these processes for any product that you develop.






We highly recommend speaking to a specialist for your clinical stream, and clinical evaluation in particular.

Do not wait until you are about to start the clinical evaluation to think about it. From the outset, think about what will be involved, who you will need to work with, how it will be executed, how to get ethics approval and so on. Everything you need should then be in place and suitably budgeted for, both in terms of time and cost, early on.

KEY

- 3rd Party Process
- eg technology Process






KEY

3rd Party Process

eg technology Process





KEY


3rd Party Process

eg technology Process



© eg technology 2023






KEY

3rd Party Process

eg technology Process






As well as looking at each stream individually, it is worth considering how these different streams interact and depend on one another. For example, during the concept generation stage, the user research will feed into your URS and lead to your concept thinking. Your PRS and your design will feed into each other as they develop. Your uFMEA will identify your UI spec, which will get incorporated into your requirement specifications and inform the design.

KEY

- 3rd Party Process
- eg technology Process





KEY


3rd Party Process

eg technology Process



© eg technology 2023






In the transfer to manufacture phase, many of the activities will be dependent on production of the pilot units.

This is because much of the formal testing (such as the summative evaluations, formal verification, compliance testing & clinical evaluations) requires production-representative units.

Depending on your suite of tests, they may need to be representative not only in terms of their functionality, but also their materials, manufacturing process, user interface, training, packaging, labelling & IFU (instructions for use) and so on.





KEY

3rd Party Process

eg technology Process



© eg technology 2023





To discuss your product design and development requirements, please book a call with one of our team:

+44 (0) 1223 813184

design@egtechnology.co.uk

www.egtechnology.co.uk